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A 45-year old man was diagnosed with desmoplastic small round cell tumor (DSRCT) with involvement of the peritoneum
and pelvis. Disease progression was observed despite systemic chemotherapy. Six months after diagnosis, he developed severe
hypoglycemia presented with seizures. He received intravenous glucose infusion and hydrocortisone with poor glycemic control,
but with seizures resolution. The investigation excluded insulinoma, adrenal, liver and GH deﬁciencies. Laboratory showed slight
rise of IGF-II and signiﬁcant increase of the ratio IGF-II : IGF-I, which is pathognomonic of non-islet cell tumor hypoglycemia
(NICTH). He received the diagnoses of NICTH related to IGF-II inappropriate production by DSRCT. Despite the attempt to
control tumormass and hypoglycemia, thepatient died 9 monthsafter diagnosis. NICTHrelated to inappropriate IGF-IIsecretion
should be investigated in all cancer patients with refractory hypoglycemia whom insulinoma and other metabolic abnormalities
were excluded from.
1.Introduction
Symptomatic hypoglycemia can represent a serious com-
plication of malignant neoplasia, usually by inappropriate
insulin secretion, which occurs, for instance, in pancreatic
islet cell tumor, or unusually by insulin-like growth factors
(IGF-I, IGF-II) secreted by tumor cells, referred as non-
islet cell tumor hypoglycemia (NICTH). Desmoplastic small
round cell tumor (DSRCT) is a rare mesenchymal malignant
neoplasia with predilection for adolescent and young adults
male patients [1]. Here we report a case of an adult male
patient diagnosed with DSRCT who developed refractory
hypoglycemia.
2.CaseReport
A 45-year-old man was admitted with a painful pelvic palpa-
ble mass and weight loss in November 2006. Pelvic CT scan
revealed a 12×11×12cm pelvic mass (Figure 1) and several
peritoneal lesions. Ultrasound-guided biopsy was performed
and cytologic analysis revealed a high-grade mesenchymal
neoplasia with small round blue cells. Immunohistochem-
istry was positive for CD99, enolase, EMA, vimentin, and
desmin and negative for 35βH11 and AE1/AE3 cytokeratins,
chromogranin, synaptophysin, WT1, CD3, CD20, CD30,
CD34, S-100, myogenin, and Myo-D1 (Figure 2). These
ﬁndings were consistent with a pelvic DSRCT with extensive
peritoneal involvement. Systemic chemotherapy based on
vincristine, doxorubicin, and cyclophosphamide, alternating
with ifosfamide and etoposide, was initiated. Disease pro-
gression was observed after four cycles. Six months after
diagnosis, the patient developed severe hypoglycemia, pre-
sentingwithseizures.Liverfunctionwasnormal,andadrenal
insuﬃciency was excluded. He received intravenous glucose
infusion and hydrocortisone with poor glycemic control. A
glucagon stimulation test, as previously described in [2],2 Case Reports in Medicine
:17:17 p
Figure 1: Pelvis CT showing a large pelvic mass.
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Figure 2:Positiveimmunohistochemistryfor(a)desmin,(b)EMA,
(c) Ki-67, (d) vimentin.
was performed with partial response (Figure 3). To better
evaluate the etiology of hypoglycemia, the glucose infusion
was interrupted for 10 minutes to enable measurements of
glucose, cortisol, GH, insulin, C-peptide, IGF-I, and IGF-
II (Table 1). With a glucose level of 7mg/dL, there was
appropriate release of cortisol and growth hormone (GH)
excluding adrenal and GH deﬁciency. While C-peptide,
insulin levels, and IGF-1 were adequately suppressed, IGF-
2 was slightly elevated with increased IGF-II and IGF-I
ratio (IGF-II/IGF-I = 22.94) (Table 1)w h i c hs u g g e s t e da
paraneoplastic non-islet cell tumor hypoglycemia related to
IGF-IIoverproductionbyDSRCT[3].Despitetheattemptto
control tumor mass and the hypoglycemia, the patient died
nine months after diagnosis.
Table 1: Laboratory tests.
Test (unit) Serum level Reference
Cortisol (μg/dL) 24 >18 if glucose <40
ACTH (pg/mL) 130 <46
Glucose (mg/dL) 7 70–100
Insulin (μU/mL) <2.5 To 25
C peptide(ng/mL) 0.6 0.4–3.6
TSH (μU/mL) 3.22 0.4–4.50
T4 free (ng/dL) 1.16 0.7–1.50
GH (ng/mL) 4.2 >3.3 if glucose <40
IGF-I (ng/mL) 65 101–267
IGF-II (ng/mL) 1491 414–1248
IGF-II/IGF-Iratio 22.94 3.8 ±1.5
−10 0 15 30
0
5
10
15
20
25
30
35
40
45
50
Time related to glucagon infusion (min)
S
e
r
u
m
g
l
u
c
o
s
e
(
m
g
/
d
L
)
Glucagon stimulation test
Figure 3: Partial response to glucagon stimulation test.
3. Discussion
DSRCT is a rare tumor composed of a desmoplastic stroma
with nests of small round blue cells with polyphenotypic
diﬀerentiation and presenting predominantly mesenchymal
diﬀerentiation. It has a predilection for adolescent and
young adult males and, primarily, involves the abdomen and
pelvis [1]. DSRCT is associated with a speciﬁc chromosomal
translocation, t(11:22) (p13:q12) [4], which juxtaposes EWS
gene to the tumor suppressor gene WT1 [1].
It usually presents with advanced disease that must
be treated in a multimodal context, based on systemic
chemotherapy, radiotherapy, and cytoreductive surgery. The
prognosis is usually poor, with few patients achieving long-
term survival [1].
The occurrence of tumor hypoglycemia not related to
insulin, though rare, has been reported in mesenchymal
neoplasms, referred to as non-islet cell tumor hypoglycemia
(NICTH). Serum levels of insulin and C-peptide must be
suppressed to exclude insulinoma [5]. In these patients, an
inappropriate (paraneoplastic) tumor production and secre-
tion of insulin-like growth factors have been described. IGF-
I and IGF-II interact with peripheral cell receptors (insulin
receptor, IGF-I receptor, and IGF-II receptor) leading to
hypoglycemia [6]. Both IGF-I and IGF-II circulate almostCase Reports in Medicine 3
completely (>90%) bound to speciﬁc IGFBPs (IGF-binding
proteins). The association of IGFs and IGFBPs with an
acid-labile subunit (ALS) results in a ternary complex. This
complex has a molecular mass of approximately 150kDa
and is virtually conﬁned to the intravascular compartment
[3]. In NICTH, post-translational processing of pro-IGF-
II is abnormal [7] resulting in hypersecretion of a higher
molecular weight form of IGF-II (“big” IGF-II). “Big”
IGF-II is biologically active and present in relatively high
amounts in the serum of NICTH patients. In most cases,
the serum level of total IGF-II is not elevated indicating
that “big” IGF-II must have speciﬁc biochemical properties
that are diﬀerent from those of mature IGF-II that lead
to an enhanced bioavailability and, consequently, increased
insulin-like activity [7]. Treatment should be directed to the
underlying neoplasia, with reports of correction of IGF-II
levels and normalization of hypoglycemia [8].
In this case, insulinoma was ruled out, and after
excluding hepatic, adrenal, and thyroid abnormalities, we
detected inappropriately high levels of circulating IGF-II
and IGF-II : IGF-I ratio, which is virtually pathognomonic
of NICTH [3]. We were unable to check for elevation
of “big IGF-II” because the assay was unavailable at our
center. The glucagon stimulation test is useful to distinguish
hypoglycemia mediated by insulin or insulin growth factors
from hypoglycemia due to liver failure. In addition, it helps
to select patients who may beneﬁt from glucagon treatment.
Despite adequate liver function, this patient did not respond
appropriately to glucagon stimulation. We believe that the
inability to present an appropriate response was probably
due to the long refractory hypoglycemia leading to depletion
of the hepatic glycogen stores.
NICTH related to inappropriate IGF-II secretion should
be investigated in all cancer patients with refractory hypo-
glycemia in whom insulinoma and other metabolic abnor-
malities were excluded.
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